Hepatitis C

$5 HCV drugs may be affecting profits

Gilead Sciences in its second-quarter report for 2017 reported that its sales of direct-acting antivirals for HCV were down about 25 percent from the same period last year (2.9 billion, compared with 4 billion). Does this mean that fewer cases of HCV are being treated, or does it mean the prices of antivirals are going down?

It’s hard to compare the prices because the company is secretive about its negotiations with insurance companies and governments. When the drugs were first on the market, wealthy patients were shelling out upwards of $100,000 for the drugs. Now, except for uninsured people or those on Medicare or Medicaid, Gilead is advertising a $5 bargain price for the drugs. Considering the exclusions, that doesn’t seem like charity, but it may be keeping Gilead’s cash coffers down.

As for the numbers of people being treated, the latest report from the World Hepatitis Alliance shows they’ve more than doubled since 2013, when 440,000 people were treated, mainly with interferon.

This entry was posted in Uncategorized. Bookmark the permalink.

DISCLAIMER

This blog is for information purposes only. The content is not intended as medical advice, diagnosis, or treatment. Should you have a medical or dermatological problem, please consult with your physician. None of the information or recommendations on this website should be interpreted as medical advice.

All product reviews, recommendations, and references are based on the author’s personal experience and impressions using the products. All views and opinions are the author’s own.

This blog post may contain affiliate links. An affiliate link means we may earn a commission if you click on a link and make a purchase, without any extra cost to you.

Please see our Disclaimer for more information.

Source Link

odiseases.com

diseases, diagnosis and treatment methods, drugs and their side effects on this site. online diseases, diagnosis and treatment methods

Related Articles

Back to top button
%d bloggers like this: